Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 160Lymphoid 80Other hematologic neoplasm 40Thoracic 7Myeloid 6Genitourinary 6Gastrointestinal 6CNS 6Sarcoma 5Dermatologic 5Head & Neck 4Endocrine 2Classical hematology 2Breast 2Tumor-Agnostic 1Gynecologic 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Pancreatic Neoplasms 1Insulinoma 1Glucagonoma 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Bortezomib × Endocrine × Clear all
NCT00104871 2018-12-19

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡